加载中
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
收盘时
US$11.81
−US$0.27 · -2.24%
盘后
US$11.90
+US$0.09 · +0.76%
10月12日 16:25 ET
盘中时间采用ET。市场数据可能有所延迟。
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
日内区间
当前US$11.81
52周区间
当前US$11.81
盘中时间采用ET。市场数据可能有所延迟。
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
日内区间
当前US$11.81
52周区间
当前US$11.81
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 414万 USD | — | — | — | — |
| 毛利 | −414万 USD | — | — | — | — |
| 研究与开发 | 6.35亿 USD | 7.96亿 USD | 3.73亿 USD | 4.37亿 USD | 1.81亿 USD |
| 销售、一般及管理费用 | 1.06亿 USD | 8924万 USD | 6277万 USD | 1.31亿 USD | 3741.4万 USD |
| 营业费用 | 7.41亿 USD | 8.85亿 USD | 4.36亿 USD | 5.68亿 USD | 2.19亿 USD |
| 利息收入 | 1458.5万 USD | 2133.4万 USD | 1772.5万 USD | — | — |
| 折旧和摊销 | 992.2万 USD | 785.5万 USD | 691.2万 USD | 138.6万 USD | 139.3万 USD |
| 营业利润 | −7.45亿 USD | −8.85亿 USD | −4.36亿 USD | −5.68亿 USD | −2.19亿 USD |
| 净利润 | −7.39亿 USD | −8.46亿 USD | −4.08亿 USD | −5.7亿 USD | −2.14亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI4399.72万0.45%98.74亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM4209.04万0.05%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF2297.99万0.02%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1488.76万0.11%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB1205.36万0.11%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO1171.46万0.06%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA790.5万0.04%218.24亿 USD0.03%US$32.66-0.40%
Simplify Health Care ETFPINK609.97万1.91%3.19亿 USD0.51%US$38.48-0.12%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHASimplify Health Care ETFPINKAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
